Remegen Co., Ltd.

This study tests a new drug called RC278 in people with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find a safe dose and see if the drug can shrink tumors. About 312 adults aged 18 to 75 with good overall health are being recruite…

This study tests a new combination of three drugs (disitamab vedotin, trastuzumab, and tislelizumab) against standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer that has high levels of a protein called HER2. The goal is to see if the new com…

This study tests a drug called telitacicept for people with ocular myasthenia gravis, a condition that causes eye muscle weakness. About 120 participants aged 12 to 80 will receive either the drug or a placebo. The goal is to see if the drug improves eye symptoms over 24 weeks wh…

This study tests whether a new drug called RC148, when combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 80 adults aged 18-75 with measurable tu…

This study tests a combination of three drugs (disitamab vedotin, pertuzumab, and toripalimab) given before surgery to people with HER2-positive breast cancer. The goal is to see if the treatment can completely eliminate the cancer in the breast and lymph nodes. About 40 adults w…

This study compares two drug combinations for people with advanced squamous non-small cell lung cancer who have not had treatment before. About 574 participants will receive either RC148 or tislelizumab, both combined with standard chemotherapy. The goal is to see which combinati…